Evidence map›Paper›PMID 40718369›Full record

ArticleInfection and drug resistance2025

Successful Treatment of Lomentospora Prolificans Infection Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report and Literature Review.

Yi-Han Yang, Chun Di, Hao Zheng, Ya Luo, Ao-Ran Zhang, Tong Su, Xiao-Dong Mo, Yu-Qian Sun, Yu Wang, Meng Lv

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi-Han Yang *Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Chun Di *Department of Clinical Laboratory, Peking University People's Hospital, Beijing, People's Republic of China.
Hao ZhengPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Ya LuoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Ao-Ran ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Tong SuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Xiao-Dong MoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Yu-Qian SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.
Meng LvPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Beijing, People's Republic of China.ORCID 0000-0001-6625-9523

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lomentospora prolificans is an opportunistic fungal pathogen known for its intrinsic multidrug resistance. This pathogen poses a significant challenge in immunocompromised individuals, particularly patients with hematologic malignancies. We present a case of a 27-year-old male diagnosed with adverse-risk acute myeloid leukemia (AML) who developed pulmonary Lomentospora prolificans infection following therapy for positive measurable residual disease (MRD) and severe chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite the pathogen's multidrug resistance and the typically poor prognosis associated with invasive infections in immunocompromised hosts, the patient achieved sustained remission and favorable outcome. This study systematically reviews Lomentospora prolificans infections following HSCT by analyzing 37 reported cases from 24 studies identified through a PubMed search. The majority of cases had acute myeloid leukemia as the most common underlying disease. Disseminated infections were predominant (83.8%), with frequent pulmonary and central nervous system involvement. Antifungal treatment strategies largely involved combination therapy, yet outcomes remained poor, with an overall survival rate of only 13.5%. These findings highlight the critical need for novel therapeutic approaches and early intervention strategies to improve patient outcomes.

Indexed as

hematopoietic stem cell transplantationLomentospora prolificansterbinafinevoriconazole

Identifiers

PMID40718369
PMCPMC12297014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.